Literature DB >> 26676561

Effect of microbubble-enhanced ultrasound on percutaneous ethanol ablation of rat walker-256 tumour.

Wenhong Gao1, Lu Qiao1, Yuejuan Gao2, Li Zhang1, Dong Zhang3, Juan Tu3, Zheng Liu4, Feng Xie5.   

Abstract

OBJECTIVES: Percutaneous ethanol ablation (PEA) is an effective method for treating small liver cancer. Microbubble-enhanced ultrasound (MEUS) can potentially promote PEA by disrupting the tumour's circulation. In this study, treatment combining MEUS and PEA was performed to find any synergistic effects in tumour ablation.
METHODS: Ten rats bearing subcutaneous Walker-256 tumours were treated by MEUS combined with PEA. The other 18 tumour-bearing rats that were treated by MEUS or PEA served as the controls. MEUS was conducted by therapeutic ultrasound (TUS) and microbubble injection. TUS was operated at a frequency of 831 KHz with a pressure amplitude of 4.3 MPa. Tumour blood perfusion was assessed by contrast-enhanced ultrasound (CEUS), and the tumour necrosis rate was determined by histological examination.
RESULTS: CEUS showed that the tumour blood perfusion almost vanished in all of the MEUS-treated tumours. The contrast peak intensity dropped 84.8 % in the MEUS + PEA-treated tumours when compared to 46.3 % (p < 0.05) in the PEA-treated tumours 24 h after treatment. The tumour necrosis rate of the combination therapy was 97.50 %, which is much higher than that of the MEUS- (66.2 %) and PEA-treated (81.0 %) tumours.
CONCLUSION: PEA combined with MEUS can induce a much more complete tumour necrosis. KEY POINTS: • This experiment demonstrated a novel method for enhancing percutaneous ethanol ablation. • Microbubble-enhanced therapeutic ultrasound is capable of disrupting tumour circulation. • Combined therapy of MEUS and PEA can induce more complete necrosis of tumours.

Entities:  

Keywords:  Contrast-enhanced ultrasound; Microbubble-enhanced ultrasound; Necrosis rate; Percutaneous ethanol ablation; Walker-256 tumour

Mesh:

Substances:

Year:  2015        PMID: 26676561     DOI: 10.1007/s00330-015-4153-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  21 in total

1.  Vascular effects induced by combined 1-MHz ultrasound and microbubble contrast agent treatments in vivo.

Authors:  Joo Ha Hwang; Andrew A Brayman; Michael A Reidy; Thomas J Matula; Michael B Kimmey; Lawrence A Crum
Journal:  Ultrasound Med Biol       Date:  2005-04       Impact factor: 2.998

2.  Significance of tumor vascularity as a predictor of long-term prognosis in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection therapy.

Authors:  H Toyoda; T Kumuda; S Nakano; I Takeda; K Sugiyama; S Kiriyama; Y Sone
Journal:  J Hepatol       Date:  1997-05       Impact factor: 25.083

3.  Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study.

Authors:  M Koda; Y Murawaki; A Mitsuda; K Oyama; K Okamoto; Y Idobe; T Suou; H Kawasaki
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

4.  Impact of microbubble-enhanced ultrasound on liver ethanol ablation.

Authors:  Qing Liu; Hongzhi Zhao; Shengzheng Wu; Xiaochen Zhao; Yu Zhong; Lu Li; Zheng Liu
Journal:  Ultrasound Med Biol       Date:  2013-03-15       Impact factor: 2.998

5.  The antivascular action of physiotherapy ultrasound on a murine tumor: role of a microbubble contrast agent.

Authors:  Andrew K W Wood; Ralph M Bunte; Jennie D Cohen; Jeff H Tsai; William M-F Lee; Chandra M Sehgal
Journal:  Ultrasound Med Biol       Date:  2007-08-27       Impact factor: 2.998

6.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

Review 7.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

8.  Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.

Authors:  T Livraghi; A Giorgio; G Marin; A Salmi; I de Sio; L Bolondi; M Pompili; F Brunello; S Lazzaroni; G Torzilli
Journal:  Radiology       Date:  1995-10       Impact factor: 11.105

9.  Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma.

Authors:  Hiroyuki Kirikoshi; Satoru Saito; Masato Yoneda; Koji Fujita; Hironori Mawatari; Takashi Uchiyama; Takuma Higurashi; Ayumu Goto; Hirokazu Takahashi; Yasunobu Abe; Masahiko Inamori; Noritoshi Kobayashi; Kensuke Kubota; Takashi Sakaguchi; Norio Ueno; Atsushi Nakajima
Journal:  Hepatol Res       Date:  2009-06       Impact factor: 4.288

10.  Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment.

Authors:  Giovanni Mauri; Emanuele Porazzi; Luca Cova; Umberto Restelli; Tania Tondolo; Marzia Bonfanti; Anna Cerri; Tiziana Ierace; Davide Croce; Luigi Solbiati
Journal:  Insights Imaging       Date:  2014-02-22
View more
  2 in total

1.  Enhancement Effect of Microbubble-Enhanced Ultrasound in Microwave Ablation in Rabbit VX2 Liver Tumors.

Authors:  Shuyi Xiao; Zhiwen Hu; Yan He; Hai Jin; Yuwen Yang; Liping Chen; Qiaoli Chen; Qiong Luo; Jianhua Liu
Journal:  Biomed Res Int       Date:  2020-01-23       Impact factor: 3.411

2.  Promoting the effect of microbubble-enhanced ultrasound on hyperthermia in rabbit liver.

Authors:  Yuwen Yang; Huanqian Luo; Yang Zhao; Lu Li; Yan He; Fen Xi; Hai Jin; Ruru Gao; Qiong Luo; Jianhua Liu
Journal:  J Med Ultrason (2001)       Date:  2022-01-24       Impact factor: 1.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.